Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis.
Kerr, Jonathan R, Petty, Robert, Burke, Beverley et al. · The Journal of infectious diseases · 2008 · DOI
Quick Summary
Researchers analyzed blood samples from 25 ME/CFS patients and 50 healthy people to look for differences in which genes were active. They found that 88 genes behaved differently in ME/CFS patients compared to healthy controls—most were working overtime, while a few were underactive. When they studied a larger group, they discovered that ME/CFS patients could be divided into 7 distinct subtypes based on their gene activity patterns, and these subtypes differed in symptom severity and how the illness affected their daily lives.
Why It Matters
This study provides objective molecular evidence that ME/CFS is not a single homogeneous condition but comprises multiple biological subtypes, which could explain why patients respond differently to treatments. Identifying gene expression signatures offers potential for developing blood-based diagnostic tests and personalized treatment strategies tailored to individual molecular profiles.
Observed Findings
88 genes showed differential expression between CFS/ME patients and healthy controls (85 upregulated, 3 downregulated)
Gene expression pathways enriched for hematological disease, immunological disease, cancer, cell death, immune response, and infection
7 distinct molecular subtypes identified via clustering of qPCR data in the validation cohort
Subtypes demonstrated significant differences in Medical Outcomes Survey Short Form-36 (SF-36) quality-of-life scores
Subtypes showed distinct differences in clinical phenotypes and disease severity
Inferred Conclusions
ME/CFS is associated with significant dysregulation of immune and hematological gene expression in peripheral blood
Patient heterogeneity at the molecular level may underlie clinical heterogeneity, suggesting ME/CFS comprises multiple biological subtypes
Gene expression profiling could stratify patients into clinically meaningful subgroups with different disease severity and functional impairment patterns
Remaining Questions
Are the 7 identified gene expression subtypes stable longitudinally, or do they change over the course of illness?
Do the molecular subtypes predict differential responses to specific treatments or interventions?
What This Study Does Not Prove
This study does not establish whether the observed gene expression changes cause ME/CFS symptoms or merely reflect the disease state—the direction of causality remains unknown. The study does not prove these gene expression patterns are stable over time or predict clinical outcomes. It also does not demonstrate that targeting these genes therapeutically would improve patient outcomes.